Albutrepenonacog alfa - CSL Behring

Drug Profile

Albutrepenonacog alfa - CSL Behring

Alternative Names: CSL 640; CSL-654; Idelvion; Recombinant factor IX - CSL Behring; Recombinant factor IX fusion protein linked with human albumin; rFIX-FP - CSL Behring; rIX-FP

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CSL Behring
  • Class Albumins; Antihaemorrhagics; Blood coagulation factors; Recombinant fusion proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia B
  • Clinical Phase Unknown Haemophilia

Most Recent Events

  • 28 Feb 2017 Clinical trials in Haemophilia (SC) before February 2017 (CSL group pipeline, February 2017)
  • 03 Dec 2016 Registered for Haemophilia B (In adolescents, In children, In adults) in Switzerland (IV) Before December 2016
  • 03 Dec 2016 Updated pooled results from the phase III PROLONG-9FP trials were presented at the 58th annual meeting of the American Society of Haematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top